Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Détails

ID Serval
serval:BIB_4DAFF0202FDC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Périodique
Nature reviews. Clinical oncology
Auteur⸱e⸱s
Fukumura D., Kloepper J., Amoozgar Z., Duda D.G., Jain R.K.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Statut éditorial
Publié
Date de publication
05/2018
Peer-reviewed
Oui
Volume
15
Numéro
5
Pages
325-340
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently, however, the majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumours and facilitate immune evasion. These abnormalities stem from elevated levels of proangiogenic factors, such as VEGF and angiopoietin 2 (ANG2); judicious use of drugs targeting these molecules can improve therapeutic responsiveness, partially owing to normalization of the abnormal tumour vasculature that can, in turn, increase the infiltration of immune effector cells into tumours and convert the intrinsically immunosuppressive tumour microenvironment (TME) to an immunosupportive one. Immunotherapy relies on the accumulation and activity of immune effector cells within the TME, and immune responses and vascular normalization seem to be reciprocally regulated. Thus, combining antiangiogenic therapies and immunotherapies might increase the effectiveness of immunotherapy and diminish the risk of immune-related adverse effects. In this Perspective, we outline the roles of VEGF and ANG2 in tumour immune evasion and progression, and discuss the evidence indicating that antiangiogenic agents can normalize the TME. We also suggest ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes, and highlight avenues of future research.
Mots-clé
Angiogenesis Inhibitors/therapeutic use, Humans, Immunotherapy/trends, Neoplasms/drug therapy, Neoplasms/immunology, Neovascularization, Pathologic/drug therapy, Neovascularization, Pathologic/immunology, Tumor Microenvironment/drug effects, Tumor Microenvironment/immunology, Vascular Endothelial Growth Factor A/immunology, Vascular Endothelial Growth Factor A/therapeutic use, Vesicular Transport Proteins/immunology, Vesicular Transport Proteins/therapeutic use
Pubmed
Web of science
Création de la notice
10/03/2018 9:21
Dernière modification de la notice
20/08/2019 14:02
Données d'usage